Table 2.
Rituximab treatment details and responses
| Case | Indication | Rtx induction dosage | Rtx maintenance dosage | ERG response | Visual field after Rtx | OCT of the macula | Visual acuity | Atb results before Rtx | Atb results after Rtx/time when sample was collected | Outcome after Rtx | Follow up after Rtx (m) | Rtx stopped because of side effects |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Failure on other tx after initial response | 1000 mg X1 | 1000 mg, 2 month intervals, (total 11 doses) |
30 Hz flicker stable | Stability | Improvement in macular edema at 14 months | Stable | 45, 50, 56 | Absence/(14 months on Rtx) | Stable | 14 | No |
| 2 | No response to other tx | 375 mg/m2 (750 mg), 4 doses at one week intervals | Same regiment 6 months later | Deterioration | Decreased sensitivity | Progression, increased granularity OD, CRAO OS | Stable | 36, 40, 46 (enolase), 68 | 46 (enolase) (level unknown)/10 months on Rtx | No response | 15 | No |
| 3 | No previous tx | 675 mg/m2 (1000 mg), 2 doses at one month intervals | - | Deterioration | Not performed | No change | Decreased | 23 (HSP27), 28, 34, 36, 39, 46 (enolase), 62 | 23 (HSP27), 28, 34, 36, 39, 46 (enolase), 62 (same level than before)/5 weeks on Rtx | No response | 6 | No |
| 4 | Failure on other tx after initial response | 750 mg/m2 (1000 mg), 2 doses at 1 week intervals | Same regiment 13 months later | Every response improved except flicker | Improved | Increased granularity OD, unchanged OS | Improved 1 line OU | Absent after first trial of immuno-therapy | - | Improved | 17 | No |
| 5 | Failure on other tx | 375 mg/m2 (635 mg), 4 doses at one week intervals | Same regiment 12 months later | Response to rechallenge | Slightly improved | Unchanged, no macular edema | Unchanged | 42,45,62, 74 |
42,45,74 (same level than before)/5 months on Rtx | Stable | 21 | Yes |
Rtx rituximab, tx treatment, Atb antibody, m months, CRAO central retinal artery occlusion